Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Deffered Revenue: 2016-2024

Historic Non-Current Deffered Revenue for Seres Therapeutics (MCRB) over the last 7 years, with Jun 2024 value amounting to $95.4 million.

  • Seres Therapeutics' Non-Current Deffered Revenue rose 0.46% to $95.4 million in Q2 2024 from the same period last year, while for Jun 2024 it was $95.4 million, marking a year-over-year increase of 0.46%. This contributed to the annual value of $95.4 million for FY2023, which is 3.17% up from last year.
  • As of Q2 2024, Seres Therapeutics' Non-Current Deffered Revenue stood at $95.4 million, which was down 0.00% from $95.4 million recorded in Q1 2024.
  • In the past 5 years, Seres Therapeutics' Non-Current Deffered Revenue ranged from a high of $95.4 million in Q4 2023 and a low of $78.4 million during Q2 2021.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $94.9 million (2023), whereas its average is $92.8 million.
  • In the last 5 years, Seres Therapeutics' Non-Current Deffered Revenue declined by 24.41% in 2020 and then climbed by 15.82% in 2023.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Non-Current Deffered Revenue stood at $85.6 million in 2020, then grew by 1.67% to $87.0 million in 2021, then increased by 6.24% to $92.4 million in 2022, then climbed by 3.17% to $95.4 million in 2023, then increased by 0.46% to $95.4 million in 2024.
  • Its Non-Current Deffered Revenue was $95.4 million in Q2 2024, compared to $95.4 million in Q1 2024 and $95.4 million in Q4 2023.